Epithelial ovarian cancer is by far the most lethal gynecological malignancy. The exploration of promising immunomarkers to predict prognosis in ovarian cancer patients remains challenging. In our research, we carried out an integrated bioinformatic analysis of genome expressions and their immune characteristics in the ovarian cancer microenvironment with validation in different experiments. We filtrated 332 differentially expressed genes with 10 upregulated hub genes from the Gene Expression Omnibus database. These genes were closely related to ovarian tumorigenesis. Subsequently, the survival and immune infiltration analysis demonstrated that the upregulation of five candidate genes, ITGB2, VEGFA, CLDN4, OCLN, and SPP1, were correlated with an unfavorable clinical outcome and increased immune cell infiltration in ovarian cancer. Of these genes, ITGB2 tended to be the gene most correlated with various immune cell infiltrations and had a strong correlation with significant M2 macrophages infiltration (r = 0.707, p = 4.71 × 10−39), while it had a moderate correlation with CD4+/CD8+ T cells and B cells. This characteristic explains why the high expression of ITGB2 was accompanied by immune activation but did not reverse carcinogenesis. Additionally, we confirmed that ITGB2 was over-expressed in ovarian cancer tissues and was mainly located in cytoplasm, detected by Western blotting and the immunohistochemical method. In summary, ITGB2 may serve as a prognostic immunomarker for ovarian cancer patients.

中文翻译：

---

将 ITGB2 鉴定为卵巢癌的潜在预后生物标志物

上皮性卵巢癌是迄今为止最致命的妇科恶性肿瘤。探索有前途的免疫标记物来预测卵巢癌患者的预后仍然具有挑战性。在我们的研究中，我们对卵巢癌微环境中的基因组表达及其免疫特征进行了综合生物信息学分析，并在不同的实验中进行了验证。我们从 Gene Expression Omnibus 数据库中筛选出 332 个差异表达基因和 10 个上调的中枢基因。这些基因与卵巢肿瘤发生密切相关。随后，生存和免疫浸润分析表明，五个候选基因 ITGB2、VEGFA、CLDN4、OCLN 和 SPP1 的上调与卵巢癌的不利临床结果和免疫细胞浸润增加相关。在这些基因中，ITGB2 往往是与各种免疫细胞浸润最相关的基因，并且与显着的 M2 巨噬细胞浸润有很强的相关性（r = 0.707，p = 4.71 × 10-39），而它与 CD4+/CD8+ T 细胞和B细胞。这一特征解释了为什么 ITGB2 的高表达伴随着免疫激活但没有逆转致癌作用。此外，我们通过Western blotting和免疫组织化学方法检测到ITGB2在卵巢癌组织中过表达，主要位于细胞质中。总之，ITGB2 可作为卵巢癌患者的预后免疫标志物。而它与 CD4+/CD8+ T 细胞和 B 细胞具有中度相关性。这一特征解释了为什么 ITGB2 的高表达伴随着免疫激活但没有逆转致癌作用。此外，我们通过Western blotting和免疫组织化学方法检测到ITGB2在卵巢癌组织中过表达，主要位于细胞质中。总之，ITGB2 可作为卵巢癌患者的预后免疫标志物。而它与 CD4+/CD8+ T 细胞和 B 细胞具有中度相关性。这一特征解释了为什么 ITGB2 的高表达伴随着免疫激活但没有逆转致癌作用。此外，我们通过Western blotting和免疫组织化学方法检测到ITGB2在卵巢癌组织中过表达，主要位于细胞质中。总之，ITGB2 可作为卵巢癌患者的预后免疫标志物。免疫印迹法和免疫组化法检测。总之，ITGB2 可作为卵巢癌患者的预后免疫标志物。免疫印迹法和免疫组化法检测。总之，ITGB2 可作为卵巢癌患者的预后免疫标志物。